Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis
<strong>Introduction<br></strong> Despite the growing evidence on efficacy, few economic evaluations have evaluated the cost-utility of Pidotimod (PDT) supplementation to decrease the probability of recurrent respiratory tract infections in children. This study aimed to determine t...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2022
|